Psoriasis
Conditions
Brief summary
Analysis of barriers in psoriasis care from the patient's and the physician's perspective and generation of scientific data on the quality of health care in Denmark, Poland, Spain, and Germany
Detailed description
Cross-sectional, non-interventional study on healthcare for psoriasis in patients and their treating physicians. Clinical data on severity as well as subjective estimates on disease burden, quality of life etc. will be collected. Data collection is planned at multiple, representative sites in fourEuropean countries with different healthcare systems with the aim to identify system-dependent and -independent barriers in guideline-compliant psoriasis care.
Interventions
OTHERnon-interventional
non-interventional survey study
Sponsors
Sandoz
Universitätsklinikum Hamburg-Eppendorf
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* clinically diagnosed psoriasis vulgaris * age ≥ 18 * written informed consent
Exclusion criteria
* lack of mental, physical or linguistic ability to participate in a questionnaire survey
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with severe disease receiving systemic treatment | Baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Psoriasis Area and Severity Index (PASI) | Baseline | Psoriasis disease severity, measured by validated instrument |
| Body Surface Area (BSA) | Baseline | Psoriasis-affected body area, measured by physician estimate |
| Dermatology Life Quality Index (DLQI) | Baseline | Quality of life assessment in dermatologic patients, measured by validated quality of life instrument |
| EuroQuol (EQ-5D) | Baseline | generic quality of life assessment, measured by validated visual analogue scale |
| Percentage of patients with comorbidities receiving treatment. | Baseline | — |
Countries
Denmark, Germany, Poland, Spain
Outcome results
None listed